Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The mammalian target of rapamycin (mTOR) is a key kinase regulating cell growth, proliferation, and survival.
• mTOR functions via two distinct complexes, mTORC1 and mTORC2.
• Aberrant activation of the mTOR pathway is a common hallmark of various cancers.

Purpose of the Study:

• To provide an overview of the signaling pathways upstream and downstream of mTORC1 and mTORC2.
• To discuss the therapeutic anticancer targets informed by mTOR pathway knowledge.
• To review both clinically tested and developing therapeutic strategies targeting the mTOR pathway.

Main Methods:

• Literature review of signaling pathways.
• Analysis of genetic events driving mTOR activation in cancer.
• Evaluation of clinical trial data for mTOR-targeted therapies.

Main Results:

• Hypoxia, nutrient deprivation, and DNA damage inhibit mTORC1.
• Constitutive activation of mTOR in cancer arises from multiple genetic events.
• Insights into mTOR signaling provide a basis for novel anticancer therapeutic strategies.

Conclusions:

• Understanding mTOR pathway dysregulation is crucial for cancer therapy.
• Targeting mTOR offers potential for developing new anticancer drugs.
• Ongoing clinical development shows promise for mTOR-targeted cancer treatments.